article · Archiv der Pharmazie
ABSTRACT MDM2 is categorised as a critical oncogenic regulator that negatively controls the tumour suppressor p53, making it an important target for cancer therapy. With the aim of restoring the p53 activity through disrupting MDM2‐p53 interaction, several strategies, including small‐molecule inhibitors, have been developed, thereby promoting cancer cell apoptosis. Numerous chemical scaffolds were widely employed in designing and synthesising MDM2 inhibitors. This review summarises the advances in structure‐based drug design and virtual screening approaches that allowed the generation of potent inhibitors with improved binding affinity, selectivity and pharmacokinetic profiles. We also discuss limitations such as chemical stability and innovative approaches such as targeted MDM2 degradation.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1002/ardp.70264
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
